Ross Marchand on FDA Delays: 'Blocking Breakthroughs' and the Cost of Regulatory Gridlock

Ross Marchand, executive director of the Taxpayers Protection Alliance, discusses his organization's report Blocking Breakthroughs, which examines FDA drug rejection rates. He said that regulatory barriers, shifting standards, and excessive risk aversion are delaying patient access to potentially life-saving treatments, even as other developed countries approve the same drugs.